PDCD1 and melanoma: Evidence however remains conflicting, with early phase clinical trials suggesting that approximately 58% of melanoma patients (n = 19) receiving IDO inhibitors combined with PD-1 inhibitors achieved a complete response (CR) of 26% and a 32% partial response (PR) [68].